M/s.La Renon Health Care Pvt. v. Union of India

In the high-stakes world of pharmaceutical patents, losing a battle at a specialized tribunal can feel like the end of the road. But what happens when a company tries to take a shortcut through the High Court instead? The Madras High Court's decision in the La Renon Health Care case is a stark reminder that the doors of Article 226 don't swing open just because you're unhappy with a technical ruling. For founders and IP professionals, this case is a masterclass in understanding where the line is drawn between supervisory review and re-litigation.

M/s. La Renon Health Care Pvt. found itself on the wrong side of a patent dispute involving Indian Patent No. 224100, a patent held by Kibow Biotech Inc. covering compositions designed to augment kidney function. La Renon had sought to revoke this patent, presumably viewing it as an obstacle to its own business in the kidney health space. The revocation application made its way to the Intellectual Property Appellate Board (IPAB), the specialized body designed to handle such disputes. However, the IPAB dismissed La Renon's application, leaving the company without the relief it wanted. Rather than accepting this outcome, La Renon escalated the matter to the Madras High Court, filing a writ petition seeking a mandamus to quash the IPAB's order and direct the Controller General of Patents to cancel Kibow Biotech's patent outright.

La Renon's argument was essentially that the IPAB got it wrong. By approaching the High Court under Article 226 of the Constitution, the company was attempting to invoke the court's supervisory jurisdiction to overturn a decision of a specialized tribunal. The implicit ask was for the High Court to step into the shoes of the IPAB, re-examine the technical and legal merits of the revocation application, and substitute its own judgment. The counter-position, rooted in established principles of administrative and constitutional law, was that the High Court is not an appellate authority over specialized tribunals like the IPAB. The court's role under Article 226 is supervisory, not appellate. The legal friction here was clear: La Renon wanted the High Court to act as a second-level appeal, while the law positioned the court as a watchdog for procedural fairness, not a re-decider of technical patent disputes.

The Madras High Court declined to grant the relief La Renon sought. The court examined the matter strictly through the lens of its supervisory jurisdiction, focusing on whether there was any procedural infirmity or palpable error on the face of the record in the IPAB's order, rather than substituting its own technical findings for those of the specialized tribunal. Finding no such procedural defect, the court ruled in favor of the respondents, effectively upholding the IPAB's dismissal of La Renon's revocation application. The outcome was a clear affirmation that the High Court would not re-litigate the substantive merits of a patent revocation dispute that had already been considered by the competent specialized body.

For founders, startup leaders, and IP professionals, the lesson is unambiguous: the High Court is not a safety net for unfavorable rulings from specialized IP tribunals. If you're challenging a patent, your real fight is at the IPAB or before the Controller of Patents, where the technical and legal merits will be scrutinized. Article 226 is reserved for situations where there is a clear procedural failure, a manifest error on the face of the record, or a violation of principles of natural justice, not for a second bite at the apple. Invest your resources in building a strong case at the right forum from the outset, because once a specialized tribunal has spoken, the High Court is highly unlikely to overturn its decision on the merits.